TRUFF - Psyched: Three Noteworthy Psychedelics M&As Colorado's Regulations Exclusive Financing & More | Benzinga
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Psychedelics biotech Cybin (NYSE: CYBN) and UK-based Small Pharma (OTCMKTS: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and outstanding securities.
The deal has already been unanimously approved by both companies’ board of directors and will next face Cybin’s shareholders meeting on or about October 12. Read more HERE.
Second Psychedelics Merger Of The Week: Silo Wellness To Buy Jamaica-Based Business For $31.9M
Silo Wellness (OTCMKTS: SILFF) has confirmed its intention to acquire all issued and outstanding securities of NUGL Inc./Kaya Group (OTCMKTS: NUGL) in an arms-length transaction valued at $31.9 (CA$43.3) million.
The news was anticipated by a recent business partnership. The deal’s number reflects the combined market cap of both companies, NUGL shares valued at $0.0344 and Silo’s at $0.0147 currently (they have both entered into a trading halt as of today.) Read more HERE.
Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions
Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement by which Otsuka America Inc., the U.S. arm of Otsuka Pharmaceutical Co., would acquire all its outstanding shares in an all-cash transaction for approximately $60 (CA$80) million. Otsuka Pharmaceutical is part of Tokyo-headquartered Otsuka Holdings (OTCMKTS: OTSKF). Read more HERE.
Colorado's Psychedelic Future Unfolds: Regulators Host Community Meetings
Representatives of the Colorado Natural Medicine Division will host five "listening sessions” throughout September and October to engage ...